Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Int J Mol Sci ; 23(9)2022 Apr 29.
Article in English | MEDLINE | ID: mdl-35563335

ABSTRACT

The microrheological phenomenon of kaolin-filled polypropylene (kaolin/PP) composites was investigated for the first time. The microviscosity of kaolin/PP composites was studied by changing the melt temperature and shear rate. Then, injection moulding experiments of rectangular microgrooves with different aspect ratios using kaolin/PP composites and mechanical property tests of the samples were carried out. The results showed that with increasing kaolin content, the microviscosity of the kaolin/PP composites gradually increases. The shear rate had the greatest influence on the microviscosity, and the kaolin content had the least influence. When the aspect ratio of rectangular microgrooves is small, with an increasing kaolin content, the microgroove filling rate increases, and the microstructured sample geometric shape replication effect is good; however, when the aspect ratio reaches 10:1, the microgroove filling rate decreases with an increasing kaolin content. The microstructured sample geometric shape replication effect is also poor, and size effects appear. Different factors control the microrheological morphology of composites with different aspect ratios, including the shear deformation and viscous flow of composites. The increase in kaolin content leads to a decrease in the friction coefficient and an increase in the wear resistance of the composites. We concluded that the best composite formulation for kaolin/PP composites in microinjection is the 7KL/PP composite with 7% kaolin. When the aspect ratio is 5:1, the reproduction of the microstructured sample geometry is the best, and the comprehensive mechanical properties of the sample are the best.


Subject(s)
Kaolin , Polypropylenes , Viscosity
2.
World J Surg Oncol ; 12: 244, 2014 Aug 01.
Article in English | MEDLINE | ID: mdl-25085112

ABSTRACT

BACKGROUND: The relationship between anemia and outcomes after radiotherapy has not been systematically addressed. The study aimed to assess the prevalence and prognostic value of anemia in patients receiving primary radiotherapy for esophageal squamous cell carcinoma (ESCC). METHODS: A total of 103 patients with ESCC were retrospectively reviewed. Anemia was defined as a hemoglobin level <12 g/dl for men and <11 g/dl for women. The 3-year and 5-year overall survival (OS) and disease-free survival (DFS) were analyzed between the anemic and non-anemic groups using the Kaplan-Meier method and the Cox proportional hazards model. RESULTS: No significant differences were observed in patient characteristics between the anemic and non-anemic groups. The prevalence of anemia was 29.1%. The 3-year and the 5-year OS were 43% and 37%, respectively, in the non-anemic group, and 20% and 17%, respectively, in the anemic group. The 3-year and the 5-year DFS were 37% and 26%, respectively, in the non-anemic group, and 13% and 10%, respectively, in the anemic group. Survival analysis using the Kaplan-Meier method showed that there was significant difference between anemia and non-anemia (P < 0.02). In a multivariate analysis, anemia was identified as a highly significant prognostic factor for 3-year OS (hazard ratio 1.916; P = 0.012) and 3-year DFS (hazard ratio 1.973; P = 0.007), independent of T stage and the status of lymph nodes, and 5-year OS (hazard ratio 1.705; P = 0.027) and 5-year DFS (hazard ratio 1.980; P = 0.005), independent of TNM stage and the status of lymph nodes. CONCLUSIONS: Anemia before primary radiotherapy was associated with poor prognosis and an increased risk of relapse, which may serve as a new prognostic factor for ESCC.


Subject(s)
Anemia/epidemiology , Carcinoma, Squamous Cell/complications , Esophageal Neoplasms/complications , Radiotherapy/adverse effects , Adult , Aged , Aged, 80 and over , Anemia/etiology , Anemia/mortality , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/radiotherapy , China/epidemiology , Esophageal Neoplasms/pathology , Esophageal Neoplasms/radiotherapy , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Staging , Prevalence , Prognosis , Retrospective Studies , Survival Rate
3.
Front Aging Neurosci ; 14: 893919, 2022.
Article in English | MEDLINE | ID: mdl-35721021

ABSTRACT

Inflammasomes are cytoplasmic complexes that form in response to exogenous microbial invasions and endogenous damage signals. Among the known inflammasomes, the activation of the NACHT (NAIP, CIITA, HET-E, and TP1 domain), leucine-rich repeat, and pyrin domain containing protein 3 (NLRP3) inflammasome is also primarily related to neuroinflammation and nerve cell damage. Previous studies reported that under the stimulation of dangerous signals like reactive oxygen species (ROS), the overexpression and interaction of thioredoxin-interacting protein (TXNIP) with NLRP3 may trigger the inflammatory response through the ROS/TXNIP/NLRP3 signaling pathway. This inflammatory response is the pathophysiological basis of some neurological and neurodegenerative diseases. The activation of inflammasome and apoptosis caused by TXNIP are widespread in brain diseases. Previous report has suggested the TXNIP/NLRP3 interaction interface. However, the comprehensive model of the TXNIP/NLRP3 interaction is still unclear. In this study, molecular docking experiments based on the existing crystal model of NLRP3 were performed to investigate the binding of TXNIP and NLRP3. Three in silico models of the TXNIP/NLRP3 complex were selected, and molecular dynamics simulations evaluated the binding stability of the possible interaction between the two proteins. The results revealed that the E690, E693, and D745 residues in NLRP3 and the K212 and R238 residues in TXNIP play a critical role in the TXNIP/NLRP3 interaction. N-terminal of TXNIP is essential in promoting the conformational changes of NLRP3, although it does not directly bind to NLRP3. Our findings reveal the possible binding mechanism between TXNIP and NLRP3 and the associated allosteric regulation of NLRP3. The constructed models may also be useful for inhibitor development targeting the TXNIP/NLRP3 interaction during inflammasome activation via the ROS/TXNIP/NLRP3 pathway.

4.
Biomed Pharmacother ; 134: 111107, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33341059

ABSTRACT

The immune system plays a pivotal role in defending against infection and cancer immunosurveillance during the onset and procession of malignant disease. Cancer patients are frequently immunocompromised and subject to refractory infection and relapse of leukemia, due to the cytotoxic agents and immunosuppressive glucocorticoids in the chemotherapy regimens. Bu Shen Hui Yang Fang (BSHY), a traditional Chinese compound, was widely used in China to enhance the immune system of leukemia patients combined with chemotherapy and effectively lowered their risk of infection, with specific mechanism unknown yet. Thus, we investigated the effects of BSHY on the immune system using immunosuppressive mouse models. By analyzing the immune system of immunosuppressed BALB/C mice induced by hydrocortisone, we found an increase of CD4+ and CD8+ lymphocytes in the spleens of mice after BSHY treatment. Furthermore, we found the enhanced immune system in BSHY treated group was due to increased proliferation and decreased apoptosis of lymphocytes. Cytokine array analysis revealed that interleukin 4 (IL-4) was reduced in the plasma of immunosuppressed mice but returned to a normal level after BSHY treatment. Moreover, we found IL-4 was an adverse prognostic factor in acute myeloid leukemia patients and part of them could be elevated by BSHY. Mechanistically, we found BSHY enhances the proliferation of lymphocytes in a Stat6-dependent manner. In summary, our current study demonstrates that BSHY enhances the proliferation of lymphocytes in the immunosuppressed mice via upregulating IL-4 signaling.


Subject(s)
Cell Proliferation/drug effects , Drugs, Chinese Herbal/pharmacology , Immunocompromised Host , Interleukin-4/metabolism , Lymphocyte Activation/drug effects , Lymphocytes/drug effects , Animals , Apoptosis/drug effects , Humans , Leukemia, Myeloid, Acute/immunology , Leukemia, Myeloid, Acute/metabolism , Lymphocytes/immunology , Lymphocytes/metabolism , Male , Mice, Inbred BALB C , STAT6 Transcription Factor/metabolism , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL